In vitro toxicity and metabolism of 2′,3′-dideoxycytidine, an inhibitor of human immunodeficiency virus infectivity

This publication has 12 references indexed in Scilit:

• Dideoxycytidine permeation and salvage by mouse leukemia cells and human erythrocytes
  Biochemical Pharmacology, 1989
• Human red blood cells as bioreactors for the release of 2′,3′-dideoxycytidine, an inhibitor of HIV infectivity
  Biochemical and Biophysical Research Communications, 1989
• Circulating p24 Antigen Levels and Responses to Dideoxycytidine in Human Immunodeficiency Virus (HIV) Infections
  Annals of Internal Medicine, 1989
• FOLLOW-UP OF NEUROPATHY FROM 2',3'-DIDEOXYCYTYTIDINE
  The Lancet, 1988
• The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species
  Biochemical Pharmacology, 1988
• PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)
  The Lancet, 1988
• Inhibition of Infectivity and Replication of HIV-2 and SIV in Helper T-Cells by 2′,3′-Dideoxynucleosides In Vitro
  AIDS Research and Human Retroviruses, 1988
• Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1
  Antimicrobial Agents and Chemotherapy, 1987
• Strategies for antiviral therapy in AIDS
  Nature, 1987
• Establishment and characterization of a human histiocytic lymphoma cell line (U‐937)
  International Journal of Cancer, 1976